Highlight
Evidence of Reno-Protection
According to data from the BMC2 registry, patients with diabetes who were receiving SGLT2 inhibitors (SGLT2i) prior to percutaneous coronary intervention (PCI) experienced a 28% reduction in the odds of developing contrast-associated acute kidney injury (CA-AKI) compared to non-users.
Consistent Clinical Benefit
The protective signal remained robust even after rigorous propensity-score matching and risk adjustment, with the benefits extending to various high-risk patient subgroups, suggesting a broad clinical utility for these agents in the catheterization lab setting.
Addressing a Critical Gap
While the long-term renal benefits of SGLT2i are well-established for chronic kidney disease and heart failure, this study provides pivotal real-world evidence regarding their efficacy in mitigating the acute, toxic effects of iodinated contrast media during invasive cardiac procedures.
Background: The Challenge of CA-AKI in Interventional Cardiology
Contrast-associated acute kidney injury (CA-AKI) remains one of the most frequent and clinically significant complications following percutaneous coronary intervention (PCI). For patients with diabetes mellitus, the risk is particularly pronounced due to underlying microvascular dysfunction, oxidative stress, and a higher prevalence of pre-existing chronic kidney disease (CKD). CA-AKI is not merely a transient elevation in serum creatinine; it is independently associated with prolonged hospitalization, increased healthcare costs, and a heightened risk of long-term progression to end-stage renal disease and major adverse cardiovascular events (MACE).
Historically, the management of CA-AKI risk has been limited to periprocedural hydration and the minimization of contrast volume. Pharmacological interventions, including N-acetylcysteine and various vasodilators, have largely failed to show consistent benefits in large-scale clinical trials. Consequently, there is an urgent need for novel therapeutic strategies that can protect the renal parenchyma from the hemodynamic and cytotoxic insults inherent in contrast administration.
SGLT2 inhibitors have revolutionized the management of type 2 diabetes, heart failure, and CKD. By inhibiting the sodium-glucose cotransporter 2 in the proximal tubule, these agents promote glycosuria and natriuresis. More importantly, they restore tubuloglomerular feedback, leading to afferent arteriolar vasoconstriction and a reduction in intraglomerular pressure. While this mechanism leads to an initial, reversible dip in the glomerular filtration rate (GFR), it ultimately preserves renal function over time. However, the role of SGLT2i in the acute setting of contrast exposure has been a subject of debate, with some clinicians concerned that the initial GFR dip might exacerbate acute injury. The BMC2 registry study provides essential clarity on this clinical dilemma.
Study Design and Methodology
The researchers utilized data from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) PCI registry, a comprehensive, multi-center clinical database that captures all PCI cases at nonfederal hospitals across the state of Michigan. This retrospective analysis focused on a contemporary cohort of patients with diabetes who underwent PCI between January 2022 and September 2023.
Inclusion and Exclusion Criteria
The study population included all diabetic patients enrolled in the registry during the study period. To ensure data integrity and clinical relevance, the researchers excluded patients currently on dialysis and those for whom post-procedural serum creatinine measurements were unavailable. The final analysis included 13,804 patients, representing a substantial real-world sample.
Study Endpoints
The primary endpoint was the incidence of CA-AKI, defined as an absolute increase in serum creatinine of ≥0.5 mg/dL from the baseline value following the PCI procedure. This definition is a standard metric used in interventional cardiology to identify clinically significant renal impairment.
Statistical Approach
To account for the inherent biases of a retrospective registry, the investigators employed a risk-adjusted, propensity-matched analysis. This methodology allowed for a balanced comparison between SGLT2i users and non-users by matching individuals based on a wide array of baseline characteristics, including age, baseline renal function, left ventricular ejection fraction, and procedural complexity. This rigorous approach enhances the reliability of the findings by minimizing the impact of confounding variables.
Key Findings: Significant Risk Reduction
The results of the BMC2 registry analysis underscore a clear and significant reno-protective effect associated with preprocedural SGLT2i therapy.
Primary Outcomes
Among the total cohort of 13,804 diabetic patients, the raw incidence of CA-AKI was 3.8% (82/2,186) in the SGLT2i user group compared to 5.2% (602/11,618) in the non-user group. This translated to an unadjusted odds ratio (OR) of 0.71 (P=0.004). Following propensity-score matching and risk adjustment, the difference remained statistically significant. In the matched analysis, the incidence of CA-AKI was 3.69% for SGLT2i users versus 4.68% for non-users, resulting in an adjusted odds ratio of 0.72 (P=0.027).
Subgroup Consistency
One of the most compelling aspects of the study was the consistency of the findings across various patient subgroups. The protective effect of SGLT2i was preserved regardless of baseline kidney function (eGFR), age, or the presence of heart failure. Even in patients traditionally considered at higher risk for CA-AKI, the use of SGLT2i was associated with a lower risk of post-procedural renal impairment.
Expert Commentary: Mechanistic Insights and Clinical Implications
Biological Plausibility
The observed reno-protection in this study is biologically plausible when considering the unique hemodynamic and metabolic effects of SGLT2 inhibitors. Contrast media causes CA-AKI through several pathways: direct toxicity to renal tubular cells, induction of oxidative stress, and profound vasoconstriction of the vasa recta, which leads to medullary hypoxia. The renal medulla is particularly susceptible to ischemic injury because it operates at a very low oxygen tension even under normal conditions.
SGLT2 inhibitors may mitigate these effects by reducing the metabolic demand of the proximal tubule. By blocking the active transport of sodium and glucose, these agents decrease the workload and oxygen consumption of the tubular cells. This metabolic sparing effect may render the kidney more resilient to the transient hypoxia induced by contrast media. Furthermore, the restoration of tubuloglomerular feedback may prevent the excessive hyperfiltration and subsequent tubular stress that can follow contrast-induced hemodynamic shifts.
Clinical Considerations and the SGLT2i Dip
A common concern in clinical practice is the temporary decrease in eGFR observed upon initiation of SGLT2i therapy. Some practitioners have questioned whether this dip might increase the risk of AKI during acute stressors like PCI. However, the BMC2 registry data suggest the opposite: the hemodynamic modifications induced by SGLT2i appear to be protective rather than harmful in the context of contrast exposure. This aligns with findings from other cardiovascular trials where SGLT2i demonstrated a reduction in AKI events across various clinical scenarios.
Managing the Risk of Euglycemic DKA
While the renal benefits are clear, clinicians must remain mindful of the risk of euglycemic diabetic ketoacidosis (DKA), particularly in the peri-operative or peri-procedural period when patients may experience dehydration or reduced oral intake. Current guidelines often suggest pausing SGLT2i for 3 to 4 days before major surgery. However, for a procedure like PCI, which is minimally invasive and often involves a rapid return to normal diet and activity, the risk-benefit ratio may favor maintaining SGLT2i therapy to harness its reno-protective effects. This study suggests that if a patient is already on these agents, they should likely be continued through the procedure, provided the patient is not at high risk for DKA.
Conclusion: A New Paradigm in Renal Protection
The findings from the BMC2 registry provide a significant contribution to our understanding of peri-procedural care in interventional cardiology. Among patients with diabetes undergoing PCI, the pre-procedural use of SGLT2 inhibitors is independently associated with a lower risk of contrast-associated acute kidney injury. This research challenges the traditional cautious approach of withholding these medications and instead highlights their potential as a proactive tool for renal preservation.
As SGLT2 inhibitors continue to solidify their place as a foundational therapy in cardiovascular and metabolic medicine, their role in acute procedural settings will likely expand. While randomized controlled trials are needed to definitively confirm these findings and establish specific timing protocols, the current evidence suggests that SGLT2i therapy offers a powerful shield for the kidneys during the high-stakes environment of the cardiac catheterization lab.
References
1. Hyder SN, Seth M, Hamilton DE, et al. Reno-Protective Effects of SGLT2 Inhibitors in Patients With Diabetes Undergoing Percutaneous Coronary Intervention: Insights From the BMC2 Registry. Circ Cardiovasc Interv. 2026 Feb 5:e015645. doi: 10.1161/CIRCINTERVENTIONS.125.015645.
2. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446.
3. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306.
4. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380(22):2146-2155.